Physician profile
Aleksandr Rozin
NPI 1750390761
$4,351.06
in general payments reported to CMS, 2019-2025
22 companies · $554 in 2025
The $554 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $493 · 2021: $676 · 2022: $436 · 2023: $528 · 2024: $501 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,068.90 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $710.89 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $626.80 | 2019-2023 | Eliquis |
| Pfizer INC. | $520.51 | 2019-2025 | |
| Abbvie INC. | $280.49 | 2021-2025 | Avycaz, Dalvance |
| Daiichi Sankyo INC. | $191.56 | 2019 | |
| Merck Sharp & Dohme LLC | $188.91 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Janssen Biotech, INC. | $110.78 | 2019 | |
| Sk Life Science, INC. | $110.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $109.54 | 2019-2024 | Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $108.67 | 2019-2020 | |
| Scpharmaceuticals INC. | $59.42 | 2024 | |
| Viiv Healthcare Company | $48.50 | 2023 | Apretude, Cabenuva |
| Global Blood Therapeutics, INC. | $40.70 | 2021 | |
| Eisai INC. | $28.46 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $24.36 | 2025 | |
| Foundation Medicine, INC. | $24.04 | 2019 | |
| Electromed, INC. | $22.66 | 2019 | |
| Phadia US INC. | $21.25 | 2019 | |
| Incyte Corporation | $20.00 | 2019 | |
| Genzyme Corporation | $18.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleksandr Rozin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.